Clinical Trials
10
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:3
Phase 2:5
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Phase 2
5 (50.0%)Phase 1
3 (30.0%)Not Applicable
1 (10.0%)phase_1_2
1 (10.0%)Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
Not Applicable
Not yet recruiting
- Conditions
- Pulmonary Tuberculoses
- Interventions
- Drug: RESP30TBDrug: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 24
- Registration Number
- NCT07073638
- Locations
- πΏπ¦
TASK Clinical Research Centre, Cape town, Bellville, South Africa
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)
Phase 1
Recruiting
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06663176
- Locations
- πΊπ¦
ARENSIA Exploratory Medicine, Kyiv, Ukraine
Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
Phase 2
Terminated
- Conditions
- Rifampicin Susceptible Pulmonary Tuberculosis
- Interventions
- Drug: HRZE
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 20
- Registration Number
- NCT06041919
- Locations
- πΏπ¦
TASK Clinical Research Centre, Cape Town, Bellville, South Africa
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Thirty Respiratory Limited
- Target Recruit Count
- 88
- Registration Number
- NCT04858451
- Locations
- π¬π§
Medicines Evaluation Unit, Manchester, United Kingdom
π¬π§The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
Phase 2
Withdrawn
- Conditions
- Respiratory Viral InfectionRespiratory Tract DiseasesCOVID-19 Respiratory Infection
- Interventions
- Drug: RESP301 (a nitric oxide generating solution)Drug: Standard of Care (SOC)
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Thirty Respiratory Limited
- Registration Number
- NCT04842331
- Locations
- π¬π§
Imperial College Healthcare NHS Trust, London, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found